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Marine Natural Products and their
Applications
Drug Candidates and their Potential as 
Anti-Infective Agents
This commentary continues to focus on the two papers cited in
the editorial and naturally also alludes to other papers as we
continue to emphasize the value of molecules derived from
terrestrial and marine species for CAM (1–8). In recent years,
marine natural product bioprospecting has yielded a consider-
able number of drug candidates (9). Most of these molecules
are still in preclinical or early clinical development but some are
already in the market, such as cytarabine, and it is predicted
that some, such as ET743 (Yondelis), will be approved in near
future. The ecology of marine natural products reveals that
many of these compounds are chemical weapons and have
evolved into highly potent inhibitors of physiological
processes in the prey, predators or competitors of the marine
organisms that utilize them for survival. Certain natural prod-
ucts isolated from marine invertebrates have been shown to be,
or are suspected to be, of microbial origin; this is now thought
to be the case for a majority of such molecules. Marine
microorganisms, whose immense genetic and biochemical
diversity is only beginning to be appreciated, may become a
rich source of novel chemical entities for discovering more
effective drugs.
According to Donia and Hamann (10), oceans are unique
resources that provide a diverse array of natural products,
primarily from invertebrates such as sponges, tunicates, bryo-
zoans and molluscs as well as from marine bacteria and
cyanobacteria. Since infectious diseases evolve and develop
resistance to existing pharmaceuticals, the marine environment
provides novel leads against fungal, parasitic, bacterial and
viral diseases. Several marine natural products, including
dolastatin 10, ecteinascidin-743, kahalalide F and aplidine,
have successfully advanced to late stages of clinical trials, and
a growing number of candidates have been selected as promis-
ing leads for extended preclinical assessment (11). Although
many marine-product clinical trials have been conducted for
cancer chemotherapy, factors such as drug resistance, emerg-
ing infectious diseases and the threat of bioterrorism, have
contributed to the interest for assessing natural ocean products
in treating infectious and parasitic diseases.
Enhancing Marine Natural Product Structural
Diversity and Bioactivity through Semisynthesis and
Biocatalysis
In recent decades, plants, animals and microbes from the
marine environment have revealed only a portion of what is
clearly an enormous resource for structurally diverse and bio-
active secondary metabolites (12). Several of these extraordina-
rily sophisticated and bioactive natural products can be isolated
in significant quantities without great difficulty. Thus, readily
available bioactive natural products provide valuable starting
materials for the rational generation of libraries of compounds
against infectious diseases, cancer and neurological targets,
prepared through semisynthesis and biocatalysis. Marine natu-
ral products that are utilized as starting materials consist of
compounds from a variety of structural classes and include:
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derivative work this must be clearly indicated.aureol, puupehenone, sarcophine, palinurin and manzamine
alkaloids. The possibility of generating diverse bioactive
products, beginning with a marine natural product scaffold, is
the direct result of improvement in the technologies employed
to harvest samples from the ocean, purify them and rapidly
characterize complex natural products and complete chemical
reactions and biotransformations in parallel. Thus, the vast
resources of the ocean can now be utilized routinely to design
and produce a multitude of products that can be evaluated as
components of drug discovery and development programs. This
is in contrast to those that require high-throughput screening
(HTS) in order to become available (13).
Novel Antitumor Agents from Invertebrates
and a Cartilaginous Fish—the Shark
Coral Reefs, Forests and Thermal Vents: The
Worldwide Exploration of Nature for 
Novel Antitumor Agents
Cragg et al. (14) considered nature as a source of medicinal
treatments for thousands of years. Plant-based systems con-
tinue to play an essential role in the primary health care of 80%
of the world’s population. Several of the effective anticancer
agents in current use are derived from nature, including the
microbially derived drugs, dactinomycin, bleomycin and doxo-
rubicin and the plant-derived drugs vinblastine, irinotecan,
topotecan, etoposide and paclitaxel. The search for novel anti-
tumor agents from natural sources is ongoing with botanists,
marine biologists and microbiologists teaming up with
chemists, pharmacologists, toxicologists and clinicians in the
investigation of coral reefs, rainforests and deep subsurface
thermal vents for novel bioactive compounds. Cytotoxic anti-
cancer candidates have been discovered from natural resources.
According to Kim and Park (15), natural products have been
regarded as important sources that could produce potential
chemotherapeutic agents. Over 50% of the anticancer drugs
approved by the United States Food and Drug Administration
since 1960 were originally derived from natural resources,
especially from terrestrial plants. Based on cytotoxicity bio-
assays, over 400 compounds have been isolated from plants,
marine organisms and microorganisms between 1996 and
2000. Recently, research on marine organisms has slowly
gained prime importance among natural product research. As a
result, almost 50% of the cytotoxic compounds have been
isolated from marine organisms such as sponges and corals.
Squalamine and cisplatin block angiogenesis and the
growth of human ovarian cancer cells with or without
HER-2 gene overexpression
At UCLA’s Jonsson Cancer Center, Dr. Richard J. Pietras,
Professor of hematology/oncology, has been awarded funds to
evaluate the efficacy of squalamine, a natural chemical (anti-
angiogenic sterol) isolated from the tissues of dogfish shark, in
cancer treatment. Pietras and colleagues will test the hypothesis
that it may be more effective to treat breast cancer cells along
with the associated blood supply system in which the tumor
grows and thrives than to treat the cancer cells alone. Pietras and
colleagues tested squalamine alone and in combination with
other antitumor therapies. Angiogenesis is important for the
growth and progression of ovarian cancers. Since HER-2 gene
overexpression is associated with cisplatin resistance in vitro
and the promotion of tumor angiogenesis in vivo, the response
of ovarian cancer cells with or without HER-2 gene over-
expression to squalamine and cisplatin has been evaluated both
in tumor xenograft models and in tissue culture. Ovarian cancer
cells with or without HER-2 overexpression have been grown as
subcutaneous xenografts in nude mice that were treated by
intraperitoneal injection with a control vehicle, cisplatin,
squalamine or cisplatin combined with squalamine. At the end
of the experiment, tumors were assessed for tumor growth inhi-
bition and for changes in microvessel density and apoptosis.
Profound growth inhibition was elicited by squalamine alone
and by combined treatment with squalamine and cisplatin for
both parental and HER-2-overexpressing ovarian tumor
xenografts. An immunohistochemical evaluation of tumors
revealed decreased microvessel density and increased apopto-
sis. Although HER-2-overexpressing tumors showed more
angiogenic and less apoptotic activity than parental cancers, the
growth of both tumor types was similarly suppressed by treat-
ment with squalamine in combination with cisplatin. Using in
vitro techniques, they found that squalamine does not directly
affect the proliferation of ovarian cells; rather, it significantly
blocks VEGF-induced activation of MAP kinase and cell
proliferation in human vascular endothelial cells. These results
suggest that squalamine is anti-angiogenic for ovarian cancer
xenografts and appears to enhance cytotoxic effects of cisplatin
chemotherapy independent of HER-2 tumor status.
Anti-HIV Activity of Natural Products from
Marine Organisms
The oceans represent virtually untapped resources from which
novel bioactive compounds can be discovered. According to
Tzileleka et al. (16), in order to combat the human immuno-
deficiency virus (HIV), diverse strategies have been developed
to analyze compounds that can be developed as therapeutic
agents. The screening of natural products derived from numer-
ous species has afforded metabolites with significant antiviral
activity against HIV. The marine environment, representing
approximately half of the global biodiversity, is an enormous
resource for novel compounds. Currently, more than 150 natu-
ral products with promising level of anti-HIV activity have
been isolated by following bioassay-guided protocols from
aqueous or organic extracts of marine organisms. Some of the
most characteristic marine metabolites that have exhibited
significant anti-HIV activity using various biochemical assays
designed for chemotherapeutic strategies are: Cyanovirin-N, a
protein from a blue green algae; various sulfated polysaccha-
rides extracted from seaweeds (i.e. Nothogenia fastigiata and
Aghardhiella tenera); the peptides tachyplesin and polyphe-
musin, which are highly abundant in the hemocyte debris of
208 Commentarythe horseshoe crabs Tachypleus tridentatus and  Limulus
polyphemus; sponge metabolites such as avarol, avarone, ilima-
quinone and several phloroglucinols; several metabolites
from marine fungi such as equisetin, phomasetin and integric
acid. Antiviral drugs are as important as antibiotics, in the
restricted sense of antibiotics being antibacterial. (17,18,19).
The biological and chemical diversity of an ocean clearly
offers a variety of unique sources of useful metabolites that
can be applied to certain diseases.
Perspectives on Novel Discoveries as
Contributors to Complementary and
Alternative Therapies
Cragg and Newman (20) have stated that an impressive number
of modern drugs have been isolated from natural sources; many
have been used in traditional medicine. The use of herbal drugs
is once more escalating in the form of complementary and alter-
native medicine (CAM). More recently, however, we have
witnessed an increasing role of microorganisms in the production
of antibiotics and other drugs for treating certain serious diseases.
At present, with less than 1% of the microbial world been
explored, the advances in procedures for microbial cultivation
and extraction of nucleic acids from environmental samples
obtained from soil and marine habitats and from symbiotic and
endophytic microbes associated with terrestrial and marine
macro-organisms will provide access to a vast untapped reservoir
of genetic and metabolic diversity. By using combinatorial chem-
ical and biosynthetic technology, novel natural product leads will
be optimized based upon biological activities that could yield
effective chemotherapeutic and other bioactive agents. Are there
renewed prospects of chemotherapy in the 21st century?
The “Golden Era in Chemotherapy” began when penicillin
was discovered in the late 1920s and continued for 20 years
with several other antibiotics being discovered (21). During
that period, it was realized that every infectious disease could
not be eliminated with the discovery of antibiotics since the
emergence of drug-resistant microbes was recognized. We are
now at the crucial stage where it is essential to explore new
strategies in order to combat infectious diseases. One possible
strategy would be to coexist with the microbes, rather than
eradicating them, as long as they do not harm the human hosts.
The first step of the process by which the pathogens infect the
host is the adherence of the microbes to the host cell surfaces.
Therefore, the method that defines the mechanism inhibiting
the adhesion of the microbes to the host cells may provide a
new tool in preventing the development of infectious diseases
without the elimination of microbes from the host. This is just
an example of the strategy by which humans and pathogens
can coexist in peace and should be taken into consideration for
the development of new types of antibiotics or “anti-infective
drugs” in the 21st century. Herein lies an enormous potential
for complementary and alternative medicine.
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